PATENT CLAIM ANALYSIS

Application Number: 16097239
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "373000"]

Abstract:
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R 1  and R 2  are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C 1 -C 4  alkyl, such as C 1 -C 2  alkyl or C 1  alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C 1 -C 4  alkoxy, such as C 1 -C 2  alkoxy or C 1  alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.

Claim (Index 23):
The method of  claim 1 , wherein at least one of the following applies to the condition treated:\n the substance-related addiction is addiction to one or more psychoactive substances; the habit or impulsive disorder is selected from pyromania, kleptomania, trichotillomania and intermittent explosive disorder; the behavioural addiction is selected from gambling disorder, binge eating disorder, excessive use of computers, the internet or video games, addition to shopping and addiction to sex; the emotionally unstable personality disturbance or disorder is selected from borderline personality disorder, aggressive personality disorder and explosive personality disorder; the eating disorder is selected from bulimia nervosa, anorexia nervosa, binge eating disorder, and compulsive eating disorders such as those which give rise to metabolic disorders or to weight gain or obesity disorders; the dopamine-agonist induced impulsive control disorder is associated with dopamine agonist treatment of Parkinson's disease or ADHD. the treatment or control of ADHD is for treatment or control of the impulsive symptoms associated with ADHD.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 97.0
- Lexical Diversity: 2.48624
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16130881', '10771036', '13835607', '14286499', '13581187']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6959858265884535
- 35 USC 102 Novelty (BERT): 0.5075381005045386
- Combined Prediction Score: 0.6771410539800621
- Mean Citation Score: 179.04591200000004
- Max Citation Score: 184.6629
- Similarity Product: 112.964690561986

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test